Diaminopyrimidines as P2X3 and P2X2/3 antagonists
US9556127B2 · kind B2 · utility
0Cited by
46References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2014 |
| Grant date | Jan 31, 2017 |
| Priority date | — |
| Expiry date | Aug 6, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/506
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I):or a pharmaceutically acceptable salt, solvate or prodrug thereof,wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.